KB-1448

Bimekizumab

45710

Background of Bimekizumab

Bimekizumab, marketed under the brand name Bimzelx, is a humanized monoclonal antibody that targets interleukins IL-17A, IL-17F, and IL-17AF. This medication is utilized in the treatment of various inflammatory conditions, including moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. It works by inhibiting key cytokines involved in inflammatory processes. In conclusion, bimekizumab represents a significant advancement in the treatment of inflammatory conditions like psoriasis and arthritis. Its selective inhibition of key cytokines offers a promising therapeutic option for patients with these challenging conditions.

Specifications

Catalog Number	KB-1448
Antibody Name	Bimekizumab
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	IL17A x IL17F
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. (July 2021). "Bimekizumab versus Secukinumab in Plaque Psoriasis". The New England Journal of Medicine. 385 (2): 142–152.
Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, et al. (July 2021). "Bimekizumab versus Adalimumab in Plaque Psoriasis". The New England Journal of Medicine. 385 (2): 130–141.
Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. (February 2021). "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial". Lancet. 397 (10273): 487–498.